Medically reviewed by a licensed endocrinologist | Evidence-based | Last updated: 2025
| Key TakeawaysTrulicity (dulaglutide) is a once-weekly injectable GLP-1 receptor agonist that lowers blood sugar and may support weight loss in adults with type 2 diabetes.It is not insulin. It works by stimulating your body’s own insulin release and reducing appetite.Common starting dose is 0.75 mg weekly; always inject on the same day each week using the pre-filled pen. |
If you or someone you know has been prescribed Trulicity, or if your doctor has mentioned it as an option, this guide covers everything you need to know.
Below, you will find how dulaglutide works, how to administer it correctly, what side effects to watch for, how it compares to similar medications, and what the research says about its role in weight management.
1. What Is Trulicity, and What Drug Class Does It Belong To?
Trulicity is the brand name for dulaglutide, a prescription medication developed by Eli Lilly and approved by the U.S. Food and Drug Administration (FDA) in September 2014 for the treatment of type 2 diabetes mellitus in adults.
Dulaglutide belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists.
This class also includes medications like semaglutide (Ozempic, Wegovy) and liraglutide (Victoza). GLP-1 agonists mimic a natural hormone your gut releases after eating, prompting the pancreas to produce insulin in response to elevated blood glucose.
Trulicity is formulated as a single-use, pre-filled auto-injector pen. It comes in four doses: 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg. The pen is designed so that patients can self-administer the injection without any drawing or measuring.
Trulicity at a Glance
| Feature | Detail |
|---|---|
| Generic name | Dulaglutide |
| Brand name | Trulicity |
| Drug class | GLP-1 receptor agonist |
| Manufacturer | Eli Lilly and Company |
| FDA approval (T2D) | September 2014 |
| Available doses | 0.75 mg, 1.5 mg, 3 mg, 4.5 mg |
| Dosing frequency | Once weekly |
| Route of administration | Subcutaneous injection |
| Approval in India (CDSCO) | Available; sold as Trulicity |
2. How Does Trulicity Work Inside Your Body?
GLP-1 is a hormone naturally released by cells in your small intestine within minutes of eating. In people with type 2 diabetes, this hormonal signalling is often impaired, leading to inadequate insulin secretion and poorly controlled post-meal blood glucose levels.
Trulicity works by binding to GLP-1 receptors on the pancreatic beta cells and activating them. This triggers a glucose-dependent insulin release: the pancreas releases insulin only when blood glucose is actually elevated. This mechanism is an important safety advantage.
Because insulin secretion is glucose-dependent, the risk of hypoglycemia (dangerously low blood sugar) is significantly lower than with traditional insulin therapy, particularly when Trulicity is used without insulin or sulfonylureas.
Beyond insulin secretion, dulaglutide has several additional mechanisms:
- Suppresses glucagon secretion (glucagon raises blood sugar; blocking it keeps glucose lower after meals)
- Slows gastric emptying, meaning food moves more slowly from the stomach to the intestine, flattening post-meal glucose spikes
- Acts on the hypothalamus to reduce appetite and promote a feeling of fullness (satiety)
- May have cardioprotective effects, demonstrated in the REWIND (Researching Cardiovascular Events with a Weekly Incretin in Diabetes) trial
In the landmark REWIND trial, published in The Lancet in 2019, dulaglutide reduced the risk of major adverse cardiovascular events (MACE) by 12% compared to placebo in patients with type 2 diabetes who had or were at risk for cardiovascular disease.
3. What Is the Right Trulicity Dosage for You?
Trulicity is started at a low dose and gradually increased based on tolerability and blood glucose response. This stepwise escalation approach helps minimize gastrointestinal side effects during the initial weeks of treatment.
Standard Dosing Schedule
| Phase | Dose | Duration | Purpose |
|---|---|---|---|
| Initiation | 0.75 mg once weekly | Minimum 4 weeks | Establish tolerability |
| Maintenance (standard) | 1.5 mg once weekly | Ongoing, per physician | HbA1c reduction target |
| Dose escalation (if needed) | 3 mg once weekly | After 4+ weeks at 1.5 mg | Further glycaemic control |
| Maximum dose | 4.5 mg once weekly | After 4+ weeks at 3 mg | Maximum glycaemic effect |
For weight management specifically, higher doses (3 mg and 4.5 mg) have shown greater reductions in body weight in clinical trials, including the AWARD-11 trial, which found that patients on 4.5 mg dulaglutide lost an average of 4.7 kg over 36 weeks compared to 2.9 kg on the 1.5 mg dose.
Your prescribing physician will determine the appropriate dose based on your HbA1c levels, kidney function, concomitant medications, and overall treatment goals. Do not adjust your dose on your own.
| Trulicity and Weight Loss: An Important DistinctionTrulicity is approved by the FDA for type 2 diabetes management, not as a standalone weight-loss medication. Any weight reduction that occurs is considered a beneficial secondary outcome. If weight management is a primary treatment goal, your doctor may discuss medications specifically approved for that indication. |
4. How to Use the Trulicity Pen: A Step-by-Step Injection Guide
The Trulicity pen is a single-use, pre-filled auto-injector. No drawing up of medication, no dose selection, and no needle attachment is required. Each pen contains one dose and is discarded after a single use.
Approved Injection Sites
| Injection Site | Notes |
|---|---|
| Abdomen (stomach) | At least 5 cm from the navel; most commonly used |
| Upper arm (outer area) | Useful if abdomen is not accessible; harder to self-administer |
| Upper thigh (front) | Rotate with abdomen to avoid lipohypertrophy |
Step-by-Step: How to Administer Trulicity
- Wash your hands thoroughly with soap and water.
- Remove the pen from the refrigerator at least 30 minutes before your injection to allow it to reach room temperature. Cold injections are more uncomfortable.
- Inspect the pen. The medication in the window should appear clear and colourless. Do not use it if it looks cloudy, discoloured, or contains particles.
- Choose your injection site and clean the skin with an alcohol swab. Let the area dry completely.
- Unlock the pen by turning the green lock ring.
- Place the base of the pen flat against your skin at a 90-degree angle.
- Press and hold the green button. You will hear two clicks: the first signals the injection has started; the second signals it is complete.
- Hold the pen against your skin for at least 5 seconds after the second click to ensure the full dose is delivered.
- Remove the pen. Do not rub the injection site.
- Dispose of the used pen in a sharps container. Never recap the needle.
Rotate injection sites each week. Injecting repeatedly into the same spot can cause lipohypertrophy (a thickened, lumpy area under the skin) that may reduce medication absorption.
You can inject Trulicity with or without food, and at any time of day. What matters most is that you inject on the same day each week.
If you miss a dose and your next scheduled dose is more than 3 days away, take it as soon as you remember. If your next scheduled dose is within 3 days, skip the missed dose and resume your regular schedule.
5. What Are the Side Effects of Trulicity?
Like all medications, Trulicity may cause side effects. Most are gastrointestinal and tend to be mild-to-moderate.
They are most common during the first few weeks of treatment and often subside as your body adjusts.
Common and Serious Side Effects
| Side Effect | Frequency | What to Do |
|---|---|---|
| Nausea | Very common (up to 21%) | Usually mild; improves with time. Take dose with food. |
| Diarrhoea | Common (up to 12%) | Stay well-hydrated. Mention to your doctor if persistent. |
| Vomiting | Common (up to 12%) | Eat smaller meals. Seek medical advice if severe. |
| Abdominal pain | Common | Usually transient. Report to doctor if severe. |
| Decreased appetite | Common | Generally considered a benefit; monitor weight changes. |
| Injection site reaction | Uncommon | Redness, swelling, or itching at the injection site. |
| Pancreatitis (severe) | Rare | Seek emergency care for severe, persistent abdominal pain. |
| Thyroid tumours (C-cell) | Unknown (preclinical data) | Contraindicated in personal/family history of MTC or MEN 2. |
| Hypoglycaemia | Low risk (when used alone) | Higher risk when combined with insulin or sulfonylureas. |
The risk of thyroid C-cell tumours was identified in rodent studies. It is not known whether this applies to humans.
However, Trulicity carries a black box warning and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Tell your doctor immediately if you develop a lump or swelling in your neck, hoarseness, difficulty swallowing, or shortness of breath, as these could be signs of thyroid problems.
6. Can Trulicity Help with Weight Loss? What the Research Shows
Weight reduction is a recognised secondary benefit of Trulicity in patients with type 2 diabetes. It is not approved as a weight-loss medication in its own right, but clinical evidence consistently shows meaningful reductions in body weight.
The AWARD-11 trial, a Phase 3 randomised controlled study published in Diabetes Care, compared three dulaglutide doses against a placebo-controlled lower-dose comparator over 36 weeks.
Patients on 4.5 mg dulaglutide lost an average of 4.7 kg (10.4 lbs), compared to 2.9 kg on the 1.5 mg dose. HbA1c reductions were also dose-dependent.
Weight Loss Outcomes: Trulicity Clinical Trials
| Trial | Dose Studied | Duration | Mean Weight Change |
|---|---|---|---|
| AWARD-11 | 4.5 mg/week | 36 weeks | -4.7 kg |
| AWARD-11 | 3 mg/week | 36 weeks | -3.1 kg |
| AWARD-11 | 1.5 mg/week | 36 weeks | -2.9 kg |
| AWARD-5 | 1.5 mg/week | 104 weeks | -2.93 kg |
| REWIND | 0.75 or 1.5 mg/week | Median 5.4 years | -1.46 kg |
Weight loss results vary between individuals. Factors that influence outcomes include baseline body weight, dietary patterns, physical activity levels, and the duration of treatment.
Patients who also adopt calorie-conscious eating habits and regular physical activity alongside Trulicity therapy typically see better outcomes than those relying on medication alone.
For patients whose primary goal is significant weight loss, their doctor may consider the MetaGo weight loss program or medications specifically approved for chronic weight management, which may achieve larger reductions in body weight.
7. How Does Trulicity Compare to Other GLP-1 Medications?
Several GLP-1 receptor agonists are available for type 2 diabetes management. The differences between them centre on dosing frequency, available forms, degree of HbA1c and weight reduction, and cardiovascular trial data. Newer agents such as tirzepatide (Mounjaro), a dual GIP/GLP-1 receptor agonist, have shown even greater weight reductions, while Rybelsus (oral semaglutide) offers a needle-free option for patients who prefer tablets.
GLP-1 Receptor Agonist Comparison
| Medication | Generic Name | Frequency | HbA1c Reduction | CV Outcomes Trial | India Availability |
|---|---|---|---|---|---|
| Trulicity | Dulaglutide | Once weekly | Up to -1.8% | REWIND (positive) | Yes |
| Ozempic | Semaglutide | Once weekly | Up to -2.0% | SUSTAIN-6 (positive) | Yes (generics available) |
| Mounjaro | Tirzepatide (dual GIP/GLP-1) | Once weekly | Up to -2.4% | SURPASS-CVOT (positive) | Yes (since March 2025) |
| Rybelsus | Semaglutide (oral) | Once daily (oral) | Up to -1.5% | PIONEER 6 (positive) | Yes |
| Victoza | Liraglutide | Once daily | Up to -1.6% | LEADER (positive) | Yes |
| Byetta | Exenatide | Twice daily | Up to -1.0% | No major CV trial | Limited |
Trulicity’s once-weekly, pre-filled single-use pen is often cited by patients as a convenience advantage over daily injections.
Unlike some GLP-1 agonists, no dose preparation, needle attachment, or refrigeration beyond standard storage is required once the pen is at room temperature.
The choice between GLP-1 agonists depends on your individual clinical profile.
Your physician will weigh your HbA1c targets, cardiovascular risk, kidney function, weight goals, and local availability before recommending a specific agent. For a comparison with liraglutide specifically, see our dulaglutide vs liraglutide guide.
8. Is Trulicity Available in India? What You Need to Know
Trulicity (dulaglutide) is available in India and has been approved by the Central Drugs Standard Control Organisation (CDSCO).
It is stocked at select specialty pharmacies and hospital pharmacies in major metropolitan areas, including Mumbai, Delhi, Bengaluru, Chennai, Hyderabad, and Pune.
The medication requires a valid prescription from a registered medical practitioner. It is not available as an over-the-counter drug.
The Indian Council of Medical Research (ICMR) and the Research Society for the Study of Diabetes in India (RSSDI) have published guidelines that recognise GLP-1 receptor agonists, including dulaglutide, as a recommended class of agents for type 2 diabetes management in appropriate patient profiles, particularly those with cardiovascular risk or obesity.
Storage: Trulicity pens must be stored in a refrigerator at 2 to 8 degrees Celsius. They may be kept at room temperature (below 30 degrees Celsius) for up to 14 days if refrigeration is temporarily unavailable. Do not freeze the pen.
The Bottom Line
| What to Remember About TrulicityTrulicity (dulaglutide) is a once-weekly injectable GLP-1 receptor agonist that helps manage blood glucose in adults with type 2 diabetes. It is not insulin. It works by triggering glucose-dependent insulin release, slowing digestion, and reducing appetite, making it a useful tool for both glycaemic control and modest weight management.Clinical trials, including the REWIND cardiovascular outcomes trial, support its safety and efficacy in patients with established or high-risk cardiovascular disease.If your doctor has recommended Trulicity, use it as directed, rotate injection sites, and attend regular follow-up appointments to monitor your HbA1c, weight, and kidney function. The medication works best as part of a broader approach that includes a balanced diet, regular physical activity, and consistent medical supervision. |
Frequently Asked Questions About Trulicity
How does Trulicity work to lower blood sugar?
Trulicity activates GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion.
It also suppresses glucagon (which raises blood sugar), slows gastric emptying, and reduces appetite by acting on the brain’s satiety centres.
Because insulin is released only when blood glucose is actually elevated, the risk of hypoglycaemia when used as monotherapy is relatively low.
Is Trulicity an insulin?
No. Trulicity is not an insulin. It is a GLP-1 receptor agonist, a completely separate drug class.
Rather than replacing insulin, it stimulates your pancreas to produce more of its own insulin in response to elevated blood glucose.
Trulicity may be prescribed alongside insulin, but it is not a form of insulin itself.
How do I administer the Trulicity pen correctly?
Allow the pen to warm to room temperature for at least 30 minutes. Choose an injection site on your abdomen, thigh, or upper arm.
Clean the skin with an alcohol swab, press the pen flat against the skin at a 90-degree angle, and press the green button until you hear two clicks.
Hold the pen in place for 5 seconds after the second click before removing it. Rotate sites weekly and discard the pen after use.
What side effects should I watch out for with Trulicity?
The most common side effects are gastrointestinal: nausea, diarrhoea, vomiting, and reduced appetite.
These are typically mild and tend to improve within the first 4 to 8 weeks. More serious but rare concerns include pancreatitis and, based on animal data, potential thyroid C-cell effects.
Seek immediate medical attention for severe, persistent abdominal pain, neck swelling, or difficulty breathing.
How does Trulicity compare to Ozempic (semaglutide)?
Both are once-weekly GLP-1 receptor agonists, but semaglutide (Ozempic) has demonstrated slightly greater reductions in HbA1c (up to -2.0%) and greater weight loss in head-to-head trials, including SUSTAIN 7.
Trulicity has more extensive long-term cardiovascular outcomes data from the REWIND trial. For a full comparison, see our semaglutide vs dulaglutide guide and our Ozempic vs Trulicity guide. The choice between the two depends on individual clinical factors, and your doctor is best placed to guide that decision.
| Medical DisclaimerThis article is for informational purposes only and does not constitute medical advice. Trulicity (dulaglutide) is a prescription medication. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. Individual results vary. |
